Display Settings:

Format

Send to:

Choose Destination
    Genes Dev. 1998 Aug 15;12(16):2469-74.

    Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.

    Source

    The University of Texas, M.D. Anderson Cancer Center, Science Park-Research Division (SPRD), Smithville, Texas 78957 USA.

    Abstract

    Cyclin D1 is part of a cell cycle control node consistently deregulated in most human cancers. However, studies with cyclin D1-null mice indicate that it is dispensable for normal mouse development as well as cell growth in culture. Here, we provide evidence that ras-mediated tumorigenesis depends on signaling pathways that act preferentially through cyclin D1. Cyclin D1 expression and the activity of its associated kinase are up-regulated in keratinocytes in response to oncogenic ras. Furthermore, cyclin D1 deficiency results in up to an 80% decrease in the development of squamous tumors generated through either grafting of retroviral ras-transduced keratinocytes, phorbol ester treatment of ras transgenic mice, or two-stage carcinogenesis.

    PMID:
    9716400
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC317082
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 2
    Figure 4
    Figure 1
    Figure 3
    Figure 5

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk